Wij zijn onze website aan het vernieuwen.

Ontdekt u nog een pagina die niet klopt of hebt u een goede suggestie, laat het ons dan weten via webmedia@umcutrecht.nl.

Deze website maakt gebruik van cookies

Deze website toont video’s van o.a. YouTube. Dergelijke partijen plaatsen cookies (third party cookies). Als u deze cookies niet wilt kunt u dat hier aangeven. Lees meer over het cookiebeleid.

dr. F.Y.F.L. (Filip) de Vos Assistant Professor - medical

  • Department of Medical Oncology

F.Y.F.L. de Vos

Contact

Research Programs

Biography

 

Education

 

1993 –   1996

 

1996 –   2000

 

2004

 

 

 

2010

 

 

 

 

Pre-MedicalSchool at Limburg   UniversityCenter,   Hasselt, Belgium 

 

MedicalSchool at University   of Antwerp, Antwerp, Belgium (MD)

 

PhD thesis: “Balance between desired and unwanted effects   of chemotherapeutic and anti-angiogenic drugs” at department of   Medical Oncology at the University    of Groningen, The   Netherlands

 

Degree: Medical Oncologist, University   of Rotterdam, The Netherlands

 

Additional training

 

2013

 

 

 

2013

 

 

2014

 

 

12th Masterclass in Clinical   Oncology by the European School of

Oncology (ESO) and European   Society of Medical Oncology

(ESMO)

 

Clinical   Trial Statistics for Non-Statisticians by the European

Organization   for Research and Treatment in Cancer (EORTC)

 

Basic   Course Legislation and Organization for Clinical Researchers

(BROK)

 

 

Professional  experience

 

2008 – 2010

 

 

2010 – 2011

 

 

2011 –   present

 

 

 

Fellow, Dept of Medical Oncology, ErasmusMedical   Center, Rotterdam,   The Netherlands

 

Staff member, Dept of Medical Oncology, Radboud   University Nijmegen Medical Centre, Nijmegen,   The Netherlands

 

Staff member, Dept of Medical Oncology, University of Utrecht,   Utrecht, the Netherlands

 

Since start of PhD thesis   extensive experience with clinical trials

 

 

Research Output (78)

Efficacy and tolerability of tremelimumab in locally advanced or metastatic urothelial carcinoma patients who have failed first-line platinum-based chemotherapy

Sharma Padmanee, Sohn Joohyuk, Shin Sang Joon, Oh Do Youn, Keam Bhumsuk, Lee Hyo Jin, Gizzi Marco, Kalinka Ewa, de Vos Filip Y.F.L., Ruscica Dario, Ferro Salvatore, Xiao Feng, Baverel Paul, Chen Cecil Chi Keung, Asubonteng Kobby, Morsli Nassim, Dirix Luc 1 jan 2020, In: Clinical Cancer Research. 26 , p. 61-70 10 p.

A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastoma

van den Bent Martin, Azaro Analia, De Vos Filip, Sepulveda Juan, Yung W. K.Alfred, Wen Patrick Y., Lassman Andrew B., Joerger Markus, Tabatabai Ghazaleh, Rodon Jordi, Tiedt Ralph, Zhao Sylvia, Kirsilae Tiina, Cheng Yi, Vicente Sergio, Balbin O. Alejandro, Zhang Hefei, Wick Wolfgang jan 2020, In: Journal of Neuro-Oncology. 146 , p. 79-89 11 p.

Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies

Noorlag Lotte, De Vos Filip Y., Kok Annemieke, Broekman Marike L. D., Seute Tatjana, Robe Pierre A., Snijders Tom J. okt 2019, In: Clinical Nutrition. 38 , p. 1986-1994 9 p.

Treatment of malignant gliomas with ketogenic or caloric restricted diets: A systematic review of preclinical and early clinical studies

Noorlag Lotte, De Vos Filip Y., Kok Annemieke, Broekman Marike L. D., Seute Tatjana, Robe Pierre A., Snijders Tom J. okt 2019, In: Clinical Nutrition. 38 , p. 1986-1994 9 p.

Occurrence of an Abscopal Radiation Recall Phenomenon in a Glioblastoma Patient Treated with Nivolumab and Re-Irradiation

Van Seggelen Wouter O., De Vos Filip Y., Röckmann Heike, Van Dijk Marijke R., Verhoeff Joost J.C. 1 sep 2019, In: Case Reports in Oncology. 12 , p. 896-900 5 p.

Occurrence of an Abscopal Radiation Recall Phenomenon in a Glioblastoma Patient Treated with Nivolumab and Re-Irradiation

Van Seggelen Wouter O., De Vos Filip Y., Röckmann Heike, Van Dijk Marijke R., Verhoeff Joost J.C. 1 sep 2019, In: Case Reports in Oncology. 12 , p. 896-900 5 p.

Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma

Gluck W. Larry, Gounder Mrinal M., Frank Richard, Eskens Ferry, Blay Jean Yves, Cassier Philippe A., Soria Jean Charles, Chawla Sant, de Weger Vincent, Wagner Andrew J., Siegel David, De Vos Filip, Rasmussen Erik, Henary Haby A. 29 jul 2019, In: Investigational New Drugs.

Cognitive functioning as predictor of survival in diffuse glioma patients

Van Kessel E., Snijders T. J., De Vos F., Fonville S., Wajer I., Ruis C., Seute T., Verhoeff J., Van Zandvoort M., Robe P. jul 2019, In: European Journal of Neurology. 26 , p. 48-48

Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.

Henegouwen Jade Maxime van Berge, Hoes Louisa Rose, van der Wijngaart Hanneke, Van der Velden Daphne Liselotte, Huitema Alwin, Cuppen Edwin P. J. G., Lugtenburg Elly J., De Vos Filip Yves Francine Leon, Bloemendal Haiko, Grunberg Katrien, Verheul Henk M. W., Gelderblom Hans, Voest Emile E. 20 mei 2019, In: Journal of Clinical Oncology. 37

Update on the Drug Rediscovery Protocol: Expanded use of existing anticancer drugs in patients with a known molecular profile.

Henegouwen Jade Maxime van Berge, Hoes Louisa Rose, van der Wijngaart Hanneke, Van der Velden Daphne Liselotte, Huitema Alwin, Cuppen Edwin P. J. G., Lugtenburg Elly J., De Vos Filip Yves Francine Leon, Bloemendal Haiko, Grunberg Katrien, Verheul Henk M. W., Gelderblom Hans, Voest Emile E. 20 mei 2019, In: Journal of Clinical Oncology. 37

All Research Output (78)
To top